Exhibit 10.65

August 25, 2016

Didier Cowling

Chief Executive Officer

Kuros Biosciences AG

Wagistrasse 25

8952 Schlieren

Switzerland

Dear Mr. Cowling,

This letter constitutes written notice of termination by Arbutus Biopharma Inc., and its parent company Arbutus Pharma Corp. (collectively “Arbutus”) of the License Agreement by and between Cytos Biotechnology Ltd and Oncore Biopharma, Inc. (predecessor in interest of Arbutus), dated December 30, 2014 (“Agreement”), pursuant to § 12.3 (Termination of the Agreement for Convenience) of said Agreement.

Yours truly,

/s/ Elizabeth Howard

Elizabeth Howard

Executive Vice President & General Counsel

Cc:     VISCHER AG

Aeschenvorstadt 4

4010 Basel

Switzerland

Attn: Dr. Matthias Staehelin